These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 27563816

  • 21. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [Abstract] [Full Text] [Related]

  • 22. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
    Wang J, Dong Y, Cai Y, Zhou L, Wu S, Liu G, Su D, Li X, Qin N, Nong J, Jia H, Zhang Q, Mu J, Zeng X, Zhang H, Zhang S, Zhang Z.
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
    [Abstract] [Full Text] [Related]

  • 23. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
    Qu Y, Che N, Zhao D, Zhang C, Su D, Zhou L, Zhang L, Wang C, Zhang H, Wei L.
    Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
    [Abstract] [Full Text] [Related]

  • 24. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
    Ma XL, Jia RN, Han K, Zhang YX.
    Zhonghua Bing Li Xue Za Zhi; 2024 Jun 08; 53(6):578-584. PubMed ID: 38825903
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY.
    J Thorac Oncol; 2016 Jul 08; 11(7):1140-52. PubMed ID: 27094798
    [Abstract] [Full Text] [Related]

  • 26. Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.
    Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR.
    J Clin Oncol; 2015 Nov 10; 33(32):3701-9. PubMed ID: 26416997
    [Abstract] [Full Text] [Related]

  • 27. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N, Ruminy P, Gravet C, Marchand V, Colasse É, Lamy A, Naoures Mear CL, Bibeau F, Marguet F, Guisier F, Salaün M, Thiberville L, Jardin F, Sabourin JC.
    Lab Invest; 2018 Mar 10; 98(3):371-379. PubMed ID: 29251734
    [Abstract] [Full Text] [Related]

  • 28. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
    Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, Mori K, Abe M, Hayashi I, Taira T, Maniwa T, Takahashi T, Endo M, Nakajima T, Ohde Y, Yamamoto N.
    Cancer; 2014 May 15; 120(10):1471-81. PubMed ID: 24700479
    [Abstract] [Full Text] [Related]

  • 29. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
    Cao H, Zheng J, Zhao J, Guo XJ, Zhou JY, Ding W, Zhou JY.
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb 12; 43(2):120-125. PubMed ID: 32062881
    [Abstract] [Full Text] [Related]

  • 30. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H, Wang Z, Zhang G, Zhang M, Zhang X, Li H, Zheng X, Ma Z.
    Cancer Med; 2020 Jan 12; 9(2):487-495. PubMed ID: 31769228
    [Abstract] [Full Text] [Related]

  • 31. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.
    Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.
    Clin Chem; 2017 Mar 12; 63(3):751-760. PubMed ID: 28073897
    [Abstract] [Full Text] [Related]

  • 32. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
    Seo AN, Yang JM, Kim H, Jheon S, Kim K, Lee CT, Jin Y, Yun S, Chung JH, Paik JH.
    Br J Cancer; 2014 May 27; 110(11):2688-99. PubMed ID: 24809777
    [Abstract] [Full Text] [Related]

  • 33. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R, Pan Y, Li C, Zhang H, Garfield D, Li Y, Ye T, Hu H, Luo X, Li H, Zhang Y, Zhang J, Zhou X, Shen L, Pao W, Sun Y, Chen H.
    J Thorac Oncol; 2014 Jun 27; 9(6):760-8. PubMed ID: 24481316
    [Abstract] [Full Text] [Related]

  • 34. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR, Suurmeijer AJ, Zhang L, Sung YS, Jungbluth AA, Travis WD, Al-Ahmadie H, Fletcher CD, Alaggio R.
    Am J Surg Pathol; 2015 Jul 27; 39(7):957-67. PubMed ID: 25723109
    [Abstract] [Full Text] [Related]

  • 35. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z, Yu X, Zhang Y.
    Cancer Biol Ther; 2017 Nov 02; 18(11):883-887. PubMed ID: 27635639
    [Abstract] [Full Text] [Related]

  • 36. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.
    Cancer Cytopathol; 2013 Sep 02; 121(9):500-7. PubMed ID: 23495083
    [Abstract] [Full Text] [Related]

  • 37. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
    Cagle PT, Raparia K, Portier BP.
    Adv Exp Med Biol; 2016 Sep 02; 890():25-36. PubMed ID: 26703797
    [Abstract] [Full Text] [Related]

  • 38. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P, Lozano MD, Vigliar E, Bellevicine C, Pepe F, Malapelle U, Troncone G.
    Cancer Cytopathol; 2017 Nov 02; 125(11):817-830. PubMed ID: 28743163
    [Abstract] [Full Text] [Related]

  • 39. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K, Mochizuki M, Kohno M, Shu S, Harada N, Yoshimura Y.
    BMC Cancer; 2019 Apr 03; 19(1):301. PubMed ID: 30943926
    [Abstract] [Full Text] [Related]

  • 40. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.
    Oncology; 2015 Apr 03; 89(3):175-86. PubMed ID: 25833149
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.